Showing 1 - 10 results of 10 for search 'Federica Cocito', query time: 0.04s Refine Results
  1. 1
    P1175: THROMBOTIC RISK IN DLBCL: A REAL-LIFE COMPARISON OF THE THROLY AND MODEL IX SCORES

    P1175: THROMBOTIC RISK IN DLBCL: A REAL-LIFE COMPARISON OF THE THROLY AND MODEL IX SCORES by Ivan Civettini, Fabrizio Cavalca, Arianna Zappaterra, Stefano Crippa, Elena Agostani, Andrea Palasciano, Laura Antolinni, Federica Cocito, Carlo Gambacorti-Passerini

    Published 2023-08-01
    Get full text
    Article
  2. 2
    Correction: Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis.

    Correction: Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis. by Alessandro Corso, Silvia Mangiacavalli, Federica Cocito, Cristiana Pascutto, Virginia Valeria Ferretti, Alessandra Pompa, Roberta Ciampichini, Lara Pochintesta, Lorenzo G. Mantovani

    Published 2014-01-01
    Get full text
    Article
  3. 3
    Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.

    Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis. by Alessandro Corso, Silvia Mangiacavalli, Federica Cocito, Cristiana Pascutto, Virginia Valeria Ferretti, Alessandra Pompa, Roberta Ciampichini, Lara Pochintesta, Lorenzo G Mantovani

    Published 2013-01-01
    Get full text
    Article
  4. 4
    Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient

    Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient by Maria Kogan, Antonio Maria Alviano, Martina Catalano, Alessandra Casiraghi, Giulia Ghilardi, Giovanni Rindone, Luisa Verga, Vincenzo L’Imperio, Carlo Gambacorti Passerini, Paolo Bonfanti, Giuseppe Lapadula, Federica Cocito, Alessandro Soria

    Published 2025-02-01
    Get full text
    Article
  5. 5
    Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies

    Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies by Federica Malighetti, Matteo Villa, Mario Mauri, Simone Piane, Valentina Crippa, Ilaria Crespiatico, Federica Cocito, Elisa Bossi, Carolina Steidl, Ivan Civettini, Chiara Scollo, Daniele Ramazzotti, Carlo Gambacorti-Passerini, Rocco Piazza, Luca Mologni, Andrea Aroldi

    Published 2024-12-01
    Get full text
    Article
  6. 6
    Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi

    Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazio... by Gloria Margiotta-Casaluci, Sara Bigliardi, Federica Cocito, Erika Meli, Luigi Petrucci, Maura Nicolosi, Ombretta Annibali, Carola Boccomini, Valentina Bozzoli, Alessia Castellino, Federica Cattina, Natalia Cenfra, Sabino Ciavarella, Sofya Kovalchuk, Francesco Rotondo, Angelo Fama, Jacopo Olivieri, Francesco Zaja

    Published 2023-03-01
    Get full text
    Article
  7. 7
    Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)

    Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NC... by Elisa Bossi, Andrea Aroldi, Lorenza Maria Borin, Luisa Verga, Diletta Fontana, Federica Cocito, Beatrice Manghisi, Giovanni Rindone, Fabrizio Cavalca, Alessia Ripamonti, Monica Raggi, Sergio Maria Ivano Malandrin, Annalisa Cavallero, Laura Antolini, Diego Bonardi, Rocco Giovanni Piazza, Carlo Gambacorti‐Passerini

    Published 2022-11-01
    Get full text
    Article
  8. 8
    P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers

    P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in... by Simonetta Viviani, Anna Vanazzi, Samuele Frassoni, Chiara Rusconi, Andrea Rossi, Alessandra Romano, Caterina Patti, Corrado Schiavotto, Roberto Sorasio, Vincenzo Marasco, Laura Lissandrini, Davide Rapezzi, Daniela Gottardi, Federica Cocito, Antonino Mulè, Guido Gini, Roberta Zanotti, Alessandro Rambaldi, Vincenzo Bagnardi, Corrado Tarella

    Published 2022-10-01
    Get full text
    Article
  9. 9
    Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome

    Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome by Anna Dodero, Anna Guidetti, Fabrizio Marino, Alessandra Tucci, Francesco Barretta, Alessandro Re, Monica Balzarotti, Cristiana Carniti, Chiara Monfrini, Annalisa Chiappella, Antonello Cabras, Fabio Facchetti, Martina Pennisi, Daoud Rahal, Valentina Monti, Liliana Devizzi, Rosalba Miceli, Federica Cocito, Lucia Farina, Francesca Ricci, Giuseppe Rossi, Carmelo Carlo-Stella, Paolo Corradini

    Published 2021-07-01
    Get full text
    Article
  10. 10
    Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

    Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi by Manuel Gotti, Roberta Sciarra, Alessandro Pulsoni, Francesco Merli, Stefano Luminari, Caterina Zerbi, Livio Trentin, Alessandro Re, Chiara Rusconi, Simonetta Viviani, Andrea Rossi, Federica Cocito, Barbara Botto, Erika Meli, Antonello Pinto, Irene Dogliotti, Guido Gini, Benedetta Puccini, Francesca Ricci, Luca Nassi, Alberto Fabbri, Anna Marina Liberati, Michele Merli, Andrea Riccardo Filippi, Maurizio Bonfichi, Valentina Zoboli, Germana Tartaglia, Giorgia Annechini, Gianna Maria D’Elia, Ilaria Del Giudice, Isabel Alvarez, Andrea Visentin, Stefano Pravato, Daniela Dalceggio, Chiara Pagani, Silvia Ferrari, Caterina Cristinelli, Tanja Lazic, Virginia Valeria Ferretti, Umberto Ricardi, Luca Arcaini

    Published 2023-04-01
    Get full text
    Article

Search Tools: